Stay updated on Dapagliflozin Impact on T2DM Risk Factors Clinical Trial
Sign up to get notified when there's something new on the Dapagliflozin Impact on T2DM Risk Factors Clinical Trial page.

Latest updates to the Dapagliflozin Impact on T2DM Risk Factors Clinical Trial page
- Check7 days agoNo Change Detected
- Check14 days agoNo Change Detected
- Check21 days agoChange DetectedThe page footer shows Revision: v3.3.2, replacing v3.2.0; this is a metadata change and does not affect study details or navigation.SummaryDifference0.1%

- Check28 days agoChange DetectedRemoved the government funding status notice from the page; this change does not affect the study content (eligibility criteria, endpoints, or results). To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check42 days agoChange DetectedNo significant changes detected on the page; the study details page remains unchanged. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check49 days agoChange DetectedAdded related topics: Type 2 diabetes and MedlinePlus Genetics on the study page. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.2%

- Check71 days agoChange DetectedUpdate: site displays new operating-status notice and new version v3.2.0; removal of a Genetics topic (Type 2 diabetes) and older version (v3.1.0) is noted.SummaryDifference3%

- Check78 days agoChange DetectedVersion update: from v3.0.2 to v3.1.0. The change is limited to the revision label; no core content or critical data appears to be altered.SummaryDifference0.1%

Stay in the know with updates to Dapagliflozin Impact on T2DM Risk Factors Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Dapagliflozin Impact on T2DM Risk Factors Clinical Trial page.